STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
25 July 2026 · filed under 835d523756df
An FDA advisory panel voted narrowly to recommend allowing compounding pharmacies to produce two peptides, BPC-157 and KPV, according to STAT News. Neither peptide has received FDA approval as a drug. STAT reports the vote as a win for Health and Human Services Secretary Robert F. Kennedy Jr.
STAT News describes both peptides as popular among consumers despite the absence of approval. BPC-157 and KPV have circulated in wellness and bodybuilding circles, marketed with claims about healing and recovery, though the report characterizes their benefits as unproven.
The panel’s recommendation would permit compounding pharmacies to prepare these peptides for patients, a practice distinct from standard drug manufacturing. Compounded drugs are typically produced by pharmacies to meet specific patient needs rather than through the FDA’s standard approval pathway, which requires clinical trials demonstrating safety and efficacy.
STAT News frames the advisory vote’s significance in terms of drug regulation and patient safety, noting that allowing compounding of unapproved peptides opens the door to their wider use. The report does not indicate the final vote tally beyond describing the outcome as narrow.
The advisory panel’s recommendation is not itself a final agency action. Advisory committees convened by the FDA provide guidance that informs, but does not bind, subsequent regulatory decisions.
This bulletin summarizes reporting published by STAT News on July 23, 2026.